XML 46 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements (Details) - USD ($)
1 Months Ended 3 Months Ended
Sep. 30, 2015
Aug. 31, 2015
Jul. 31, 2014
Feb. 29, 2012
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
GlaxoSmithKline [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Proceeds from license fees received     $ 6,000,000          
Revenue recognized $ 6,500,000           $ 5,000,000  
Term of milestone agreement     3 years          
Duration of technology transfer     3 years          
Minimum milestone receivable     $ 5,750,000.00          
Maximum milestone receivable     $ 38,500,000.0          
License extension acceptance period     3 years          
Termination notice period     90 days          
License and services revenue         $ 500,000 $ 500,000    
Deferred revenue         2,500,000     $ 3,000,000
Technology Transfer, Collaboration and License Agreement [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Termination notice period   30 days            
Technology Transfer, Collaboration and License Agreement [Member] | Merck [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Proceeds from license fees received   $ 5,000,000            
Revenue recognized $ 5,000,000              
Contingent payment, completion of milestones and agreement   8,000,000            
Potential royalty revenue   $ 15,000,000            
Duration of license agreement   3 years            
Right of refusal period   5 years            
Termination notice period   90 days            
License and services revenue         600,000      
Deferred revenue         3,300,000     4,000,000
Upfront License fee, period for recognition   2 years            
Contingent termination revenue   $ 8,000,000            
Supply Agreement [Member] | Merck [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
License and services revenue         300,000 $ 500,000    
Deferred revenue         $ 2,300,000     $ 1,000,000
Term of collaborative research and development agreement (years)       5 years        
Optional extension period       5 years        
Upfront License fee, period for recognition       5 years        
Minimum [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Merck [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Duration of technology transfer   15 months            
Maximum [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Merck [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Duration of technology transfer   24 months